Replies to post #26710 on Amarin Corp Plc (AMRN)

[Chabojilo]

REDUCE-IT success would likely mean a Vascepa script with every statin script, I don't think Generics would be able to satisfy the supply need if it plays out this way, they couldn't justify the production since they'd only be allowed to market it to the Very High trig population. (generics that is)

[sts66]

I have no fear of ANDA filings and generics stealing our still slim market share, the patent portfolio locks up protection for many, many years - it's the cost of contesting the filings in court that is worrisome. Teva, Par, and every other big generic maker can afford to bleed AMRN to a certain death unless they partner with another BP with deep pockets and 100 lawyers on retainer - dunno if Kowa is up to the task, know nothing about their financials, private company.

Edit: A little OT, but patent trolls are taking their toll on many industries - anyone ever hear of Adam Corolla's podcast? He was the first comedian to move from TV/Radio to podcasting, and hugely successful at it. In a mind boggling decision, someone at the USPTO decided that a podcast, or a serialized event like a playlist, was worthy of a patent (!?!?!). Adam got sued and is fighting back, going to viral funding sites to raise the $1.5M -$3M estimated for court costs. Apple settled for a mere $8M - they probably make that in one minute. It's the sheer existence of such a broad patent that makes the system appear to by run by lunatics!